Alantra advises Venture Life Group PLC on the sale of its CDMO business to BioDue S.p.A.

May 2025

Sell-side advisory

London –  Alantra has acted as the M&A financial adviser to Venture Life Group PLC (“Venture Life” or “the Group”), a UK-based consumer healthcare company, on the approximately €62.0 million sale of its contract development and manufacturing operations– Biokosmes SRL and Rolf Kullgren AB – (together, the “CDMO Business”) and selected non-core products (the “Non-Core Products”) to BioDue S.p.A. (“BioDue”), an Italian food supplements, medical devices and cosmetics contract development and manufacturing organisation (“CDMO”) headquartered in Italy and a portfolio company of The Riverside Company.

Venture Life is an international self-care company focused on the development and commercialisation of consumer healthcare products. Its portfolio includes brands such as Balance Activ, Earol®, Lift, Glucogel, Health & Her, Gelclair, Pomi-T, UltraDEX, and Dentyl, sold in over 90 countries worldwide.
Founded in 1986, BioDue is one of the leading dietary supplements and medical devices companies in Italy and provides customers with a full-service offering, including raw material sourcing, development and formulation, production, packaging, regulatory affairs and commercialisation. Its product portfolio comprises food supplements, medical devices and cosmetics.

By divesting its capital-intensive manufacturing operations, Venture Life will direct increased cashflow into the commercialisation, growth and development of its core brands and use its financial resources to seek and select further complementary acquisitions of products and assets across the UK, US and Europe. On completion of the sale, Venture Life will enter into a 10-year development and manufacturing agreement under which Biokosmes and Rolf Kullgren will continue to provide development and manufacturing services to the Group as part of BioDue’s wider organisation.

Matthew Wiseman, Managing Director at Alantra, commented: “This transaction represents a strategically significant step for Venture Life, enabling the business to focus on its high-growth branded portfolio while maintaining secure, long-term access to high-quality manufacturing. We are proud to have supported the team in delivering this important milestone, providing deep sector expertise, strategic advice, and process execution.”

Charles Lanceley, Managing Director at Alantra, added: “This transaction underscores the increasing strategic focus within the CDMO sector of product format and capability diversification. It has been a pleasure to support Venture Life on a deal that highlights the strategic value of specialist development and manufacturing platforms and the long-term opportunities they offer to consolidators like BioDue.”

Jerry Randall, Chief Executive Officer at Venture Life, said: “I am delighted to announce this Sale and to have achieved a 11x the Target Assets’ EBITDA for FY 24. This is an exciting transaction and achieves many objectives for Venture Life, in particular it enables us to become a pure play consumer healthcare platform with a strategic focus on products and brands that support proactive, healthy longevity in their customer base.”

This transaction is another important credential to continue Alantra’s strong track record in the health, beauty and wellness sector. The team has announced thirteen sell-side transactions over the past fifteen months including the sales of Mibelle Group to Persán, Perrigo’s European CDMO to DCC Healthcare, Dr.G skincare to L’Oréal and Windstar Medical to Merz Pharma.